Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $645.9 million.

  • BridgeBio Pharma's Cash & Current Investments rose 59.20% to $645.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 37.58%. This contributed to the annual value of $681.1 million for FY2024, which is 56.62% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Cash & Current Investments of $645.9 million as of Q3 2025, which was down 14.66% from $756.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash & Current Investments registered a high of $919.1 million during Q1 2021, and its lowest value of $352.9 million during Q2 2023.
  • In the last 3 years, BridgeBio Pharma's Cash & Current Investments had a median value of $540.6 million in 2025 and averaged $535.1 million.
  • In the last 5 years, BridgeBio Pharma's Cash & Current Investments plummeted by 48.74% in 2023 and then spiked by 59.20% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Cash & Current Investments (Quarterly) stood at $393.9 million in 2021, then increased by 5.25% to $414.6 million in 2022, then climbed by 4.89% to $434.9 million in 2023, then surged by 56.62% to $681.1 million in 2024, then surged by 59.20% to $645.9 million in 2025.
  • Its last three reported values are $645.9 million in Q3 2025, $756.9 million for Q2 2025, and $540.6 million during Q1 2025.